Literature DB >> 29766285

Impact of left ventricular hypertrophy on myocardial injury in patients with ST-segment elevation myocardial infarction.

Thomas Stiermaier1,2, Janine Pöss1,2, Charlotte Eitel1,2, Suzanne de Waha1,2, Georg Fuernau1,2, Steffen Desch3, Holger Thiele3, Ingo Eitel4,5.   

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH) has been suggested as a determinant of outcome in patients with ST-segment elevation myocardial infarction (STEMI). However, available data are inconclusive and the underlying mechanisms remain unclear. Therefore, the aim of this study was to evaluate the impact of LVH on myocardial injury and clinical outcome in a large multicenter STEMI population.
METHODS: Cardiovascular magnetic resonance was performed in 795 patients within 10 days after STEMI to assess left ventricular (LV) mass and parameters of myocardial injury. Gender-specific cutoff values of indexed LV mass were used to define LVH (67 g/m2 for men and 61 g/m2 for women). Rates of major adverse cardiac events (MACE) were determined at 12-month follow-up.
RESULTS: LVH was present in 438 patients (55%) and associated with a significantly larger infarct size [18.3% of LV mass (%LV) versus 14.0%LV; p < 0.01], a lower myocardial salvage index (47.8 versus 54.4; p < 0.01), larger extent of microvascular obstruction (0.4 versus 0%LV; p < 0.01) and lower LV ejection fraction (47.9 versus 53.2%; p < 0.01) compared to STEMI patients without LVH. The effect of LVH on LV ejection fraction, infarct size and myocardial salvage index remained statistically significant after adjustment for baseline characteristics (p < 0.01 for all). MACE rates at 12 months were numerically higher in patients with versus without LVH without reaching statistical significance (7.5 versus 5.6%; p = 0.32).
CONCLUSION: In STEMI patients, LVH is associated with more pronounced structural and functional alterations in CMR imaging as an indicator for adverse clinical outcomes in STEMI survivors.

Entities:  

Keywords:  Cardiac magnetic resonance imaging; Left ventricular hypertrophy; Myocardial injury; Prognosis; ST-segment elevation myocardial infarction

Mesh:

Year:  2018        PMID: 29766285     DOI: 10.1007/s00392-018-1273-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  31 in total

1.  Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension.

Authors:  C G Missouris; S M Forbat; D R Singer; N D Markandu; R Underwood; G A MacGregor
Journal:  J Hypertens       Date:  1996-08       Impact factor: 4.844

2.  Influence of left ventricular hypertrophy on infarct size and left ventricular ejection fraction in ST-elevation myocardial infarction.

Authors:  Łukasz A Małek; Mateusz Spiewak; Mariusz Kłopotowski; Joanna Petryka; Łukasz Mazurkiewicz; Mariusz Kruk; Cezary Kępka; Jolanta Miśko; Witold Rużyłło; Adam Witkowski
Journal:  Eur J Radiol       Date:  2011-02-15       Impact factor: 3.528

3.  Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.

Authors:  Anil Verma; Alessandra Meris; Hicham Skali; Jalal K Ghali; J Malcolm O Arnold; Mikhail Bourgoun; Eric J Velazquez; John J V McMurray; Lars Kober; Marc A Pfeffer; Robert M Califf; Scott D Solomon
Journal:  JACC Cardiovasc Imaging       Date:  2008-09

4.  Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy.

Authors:  K Rakusan; M F Flanagan; T Geva; J Southern; R Van Praagh
Journal:  Circulation       Date:  1992-07       Impact factor: 29.690

5.  A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study.

Authors:  Michel G Khouri; Ronald M Peshock; Colby R Ayers; James A de Lemos; Mark H Drazner
Journal:  Circ Cardiovasc Imaging       Date:  2010-01-08       Impact factor: 7.792

6.  The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury.

Authors:  Oliver Turschner; Jan D'hooge; Christoph Dommke; Piet Claus; Erik Verbeken; Ivan De Scheerder; Bart Bijnens; George R Sutherland
Journal:  Eur Heart J       Date:  2004-05       Impact factor: 29.983

7.  Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study.

Authors:  D Levy; D D Savage; R J Garrison; K M Anderson; W B Kannel; W P Castelli
Journal:  Am J Cardiol       Date:  1987-04-15       Impact factor: 2.778

8.  Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography.

Authors:  Teresa S M Tsang; Marion E Barnes; Bernard J Gersh; Yasuhiko Takemoto; A Gabriela Rosales; Kent R Bailey; James B Seward
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

9.  Troponin-I concentration 72 h after myocardial infarction correlates with infarct size and presence of microvascular obstruction.

Authors:  John F Younger; Sven Plein; Julian Barth; John P Ridgway; Stephen G Ball; John P Greenwood
Journal:  Heart       Date:  2007-05-31       Impact factor: 5.994

Review 10.  Normal values for cardiovascular magnetic resonance in adults and children.

Authors:  Nadine Kawel-Boehm; Alicia Maceira; Emanuela R Valsangiacomo-Buechel; Jens Vogel-Claussen; Evrim B Turkbey; Rupert Williams; Sven Plein; Michael Tee; John Eng; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2015-04-18       Impact factor: 5.364

View more
  7 in total

1.  Global longitudinal strain by feature tracking for optimized prediction of adverse remodeling after ST-elevation myocardial infarction.

Authors:  Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Dorothea Eisner; Laura Riepl; Mathias Pamminger; Benjamin Henninger; Agnes Mayr; Johannes P Schwaiger; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler
Journal:  Clin Res Cardiol       Date:  2020-04-15       Impact factor: 5.460

2.  Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction.

Authors:  Sören J Backhaus; Johannes T Kowallick; Thomas Stiermaier; Torben Lange; Alexander Koschalka; Jenny-Lou Navarra; Joachim Lotz; Shelby Kutty; Boris Bigalke; Matthias Gutberlet; Hans-Josef Feistritzer; Gerd Hasenfuß; Holger Thiele; Andreas Schuster; Ingo Eitel
Journal:  Clin Res Cardiol       Date:  2019-07-05       Impact factor: 5.460

3.  The effect of cardiac geometry variation according to sex and race on outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Edward T Ha; Marc Cohen; Theodore J Gaeta; Manish A Parikh; Stephen J Peterson; Wilbert S Aronow
Journal:  Arch Med Sci Atheroscler Dis       Date:  2021-07-19

4.  Eccentric hypertrophy predicts adverse events in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Authors:  Edward T Ha; Marc Cohen; Stephen J Peterson; Wilbert S Aronow
Journal:  Arch Med Sci Atheroscler Dis       Date:  2021-04-09

5.  The Rise of ST-Elevation Myocardial Infarction in Women of Northeast China.

Authors:  Yihe Wang; Gary S Newsome
Journal:  Gerontol Geriatr Med       Date:  2021-02-15

6.  Prognostic value of left ventricular hypertrophy in postoperative outcomes in type A acute aortic dissection.

Authors:  Yifan Zuo; Yun Xing; Zhiwei Wang; Zhiyong Wu; Zhipeng Hu; Rui Hu; Feng Shi; Tianyu Liu; Liang Liu
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

7.  Clinical Characteristics Predicting Worse Long-Term Outcomes in Patients with Myocardial Infarction and Non-Obstructive Coronary Arteries (MINOCA).

Authors:  Piotr Szolc; Łukasz Niewiara; Paweł Kleczyński; Krzysztof Bryniarski; Elżbieta Ostrowska-Kaim; Kornelia Szkodoń; Piotr Brzychczy; Krzysztof Żmudka; Jacek Legutko; Bartłomiej Guzik
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.